Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04042753 · ClinicalTrials.gov registry record · Phase 2

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

A Phase 2 study of Pituitary Tumor and Pituitary, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
9
Enrollment target
8
Study locations

NCT04042753: Active Phase 2 study of Pituitary Tumor and Pituitary, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04042753 is a Phase 2 study of Pituitary Tumor and Pituitary that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 422-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04042753, a Phase 2 study of Pituitary Tumor and Pituitary, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
9 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Primary Outcome

Radiographic response rate will be assessed by RANO/iRANO

Conditions Studied

Pituitary Tumor Pituitary Pituitary Carcinoma Pituitary Cancer

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab

Study Locations (8)

New York

  • Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2019-07-31
Est. Completion 2026-07
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04042753 still lists

NCT04042753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 422-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Pituitary Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT04042753 lists 8 locations in 3 states (New York, New Jersey, California).

Frequently Asked Questions

What is clinical trial NCT04042753 about?

NCT04042753 is a clinical study titled "Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors". The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

What is the current status of trial NCT04042753?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-07-31. Estimated completion is 2026-07.

What conditions does trial NCT04042753 study?

This clinical trial studies the following conditions: Pituitary Tumor, Pituitary, Pituitary Carcinoma, Pituitary Cancer.

What interventions are being tested in trial NCT04042753?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).

Who is sponsoring clinical trial NCT04042753?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04042753 being conducted?

This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pituitary Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04042753, the US trial registry maintained by the National Library of Medicine. NCT04042753 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.